Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02736474 |
Recruitment Status :
Completed
First Posted : April 13, 2016
Last Update Posted : July 11, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obese Cigarette-smoking Schizophrenia | Drug: Naltrexone Drug: Placebo Naltrexone Drug: Bupropion Drug: Placebo Bupropion | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 22 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia |
Actual Study Start Date : | May 2016 |
Actual Primary Completion Date : | July 2018 |
Actual Study Completion Date : | July 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Naltrexone and Bupropion
Naltrexone 3 tablets(15mg) once per day and Bupropion 1 capsule(150mg) once per day in the first two weeks. Then Naltrexone 5 tablets(25mg) once per day and Bupropion 2 capsules(300mg) once per day during the rest of the study.
|
Drug: Naltrexone
3 tablets(15mg) once per day in the first two weeks,then Naltrexone 5 tablets(25mg) once per day during the rest of the study. Drug: Bupropion 1 capsule(150mg) once per day in the first two weeks,then 2 capsules(300mg) once per day during the rest of the study. |
Placebo Comparator: Placebo Naltrexone and Bupropion
Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
|
Drug: Placebo Naltrexone
Placebo Naltrexone created and masked by the pharmacy to be used as a control. Drug: Placebo Bupropion Placebo Bupropion created and masked by the pharmacy to be used as a control. |
- Change from baseline in weight at 24 weeks [ Time Frame: Baseline, 24 weeks ]evaluate all participants' weight ,weight in kilograms
- Numbers of participants who quit smoking [ Time Frame: 24 weeks ]evaluate all participants' smoking statues by Exhale carbon monoxide concentrations in part per million。
- Changes from Baseline Craving for nicotine assessed by Visual Analog Scales (VAS) at 24 weeks [ Time Frame: Baseline, 24 weeks ]evaluate all participants' craving for nicotine by Visual Analog Scales (VAS)
- Depression status assessed by Self-rating depression scale(SDS) [ Time Frame: Baseline,2,4,12,and 24 weeks ]evaluate all participants' depression status by Self-rating depression scale(SDS)
- Anxiety status assessed by Self-Rating Anxiety Scale(SAS) [ Time Frame: Baseline,2,4,12,and 24 weeks ]evaluate all participants' depression status by Self-Rating Anxiety Scale(SAS)
- Clinical symptoms assessed by the Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Baseline,2,4,12,and 24 weeks ]evaluate all participants' Clinical symptoms by the Positive and Negative Syndrome Scale (PANSS)
- Clinical symptoms assessed by clinical global impressions scale(CGI) [ Time Frame: Baseline,2,4,12,and 24 weeks ]evaluate all participants' Clinical symptoms by clinical global impressions scale(CGI)
- Change from baseline in waist circumference at 24 weeks [ Time Frame: Baseline, 24 weeks ]evaluate all participants' waist circumference,waist circumference in centimeters
- Change in Fasting Blood Glucose Levels [ Time Frame: Baseline,12 and 24 weeks ]
- Change in Fasting Insulin Levels [ Time Frame: Baseline,12 and 24 weeks ]
- Change in glycosylated hemoglobin [ Time Frame: Baseline,12 and 24 weeks ]
- Change in Fasting Triglycerides Levels [ Time Frame: Baseline,12 and 24 weeks ]
- Change in Fasting HDL Cholesterol Levels [ Time Frame: Baseline,12 and 24 weeks ]
- Change in Homeostasis Model Assessment-Insulin Resistance Levels [ Time Frame: Baseline,12 and 24 weeks ]
- Change in Fasting LDL Cholesterol [ Time Frame: Baseline,12 and 24 weeks ]
- Change in leptin [ Time Frame: Baseline,12 and 24 weeks ]
- Change in ghrelin [ Time Frame: Baseline,12 and 24 weeks ]
- Resting state functional connectivity of the brain reward circuits on weight loss and smoking cessation [ Time Frame: Baseline,24 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of schizophrenia by the International Classification of Diseases 10th Revision (ICD-10);
- age between 18 and 65 years old;
- on stable antipsychotic medication treatment for at least one month;
- BMI > 28 kg/m2 according to BMI criterion for obesity in the Chinese population , or BMI>27 kg/m2 in the presence of dyslipidemia, or male with waist circumference over 90cm;
- smoking at least 10 cigarettes daily for one year or longer;
- desire to lose weight and quit smoking.
Exclusion Criteria:
- Binge eating or other eating disorders;
- Current use of weight loss or antidiabetic medications;
- Current substance use (except nicotine or caffeine);
- Elevated hepatic transaminase levels (>2.5x normal range);
- Clinically significant Thyroid Stimulating Hormone(TSH) and/or thyroxine4(T4) abnormalities;
- History of seizure disorder;
- History of unstable cardiac problems or other unstable medication conditions;
- Being pregnant or nursing (for women).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02736474
Principal Investigator: | Jiang Du, PhD | Chief Physician |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | DU, Jiang, Chief Physician, Shanghai Mental Health Center |
ClinicalTrials.gov Identifier: | NCT02736474 History of Changes |
Other Study ID Numbers: |
MZhao-005 |
First Posted: | April 13, 2016 Key Record Dates |
Last Update Posted: | July 11, 2018 |
Last Verified: | July 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Bupropion hydrochloride, naltrexone hydrochoride drug combination Naltrexone Bupropion Alcohol Deterrents Narcotic Antagonists Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Antidepressive Agents, Second-Generation |
Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Anti-Obesity Agents |